These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 37715853)
1. Real-World Treatment Patterns and Outcomes Following First-Line Pertuzumab and Trastuzumab Among Patients with HER2+ Metastatic Breast Cancer. Mehta S; Xie J; Ionescu-Ittu R; Nie X; Kwong WJ Oncol Ther; 2023 Dec; 11(4):481-493. PubMed ID: 37715853 [TBL] [Abstract][Full Text] [Related]
2. A real-world study of treatment sequences and second-line clinical outcomes in patients with HER2-positive metastatic breast cancer in US community practice. Varghese D; Cruz GI; Johanson C; Toland L; Miranda M; Faherty EC; Harland D; Kaplan HG Int J Clin Oncol; 2024 Jun; 29(6):780-789. PubMed ID: 38528295 [TBL] [Abstract][Full Text] [Related]
3. Efficacy of trastuzumab emtansine (T-DM1) and lapatinib after dual HER2 inhibition with trastuzumab and pertuzumab in patient with metastatic breast cancer: Retrospective data from a French multicenter real-life cohort. Moinard-Butot F; Saint-Martin C; Pflumio C; Carton M; Jacot W; Cottu PH; Diéras V; Dalenc F; Goncalves A; Debled M; Patsouris A; Mouret-Reynier MA; Vanlemmens L; Leheurteur M; Emile G; Ferrero JM; Desmoulins I; Uwer L; Eymard JC; Cheaib B; Courtinard C; Bachelot T; Chevrot M; Petit T Breast; 2022 Jun; 63():54-60. PubMed ID: 35299035 [TBL] [Abstract][Full Text] [Related]
4. Real-World Treatment Patterns and Economic Burden Following First-Line Trastuzumab in Patients with Metastatic Gastric Cancer in the USA. Barzi A; Lin F; Song J; Lam C; Nie X; Noman A; Kwong WJ Drugs Real World Outcomes; 2023 Sep; 10(3):395-404. PubMed ID: 37540381 [TBL] [Abstract][Full Text] [Related]
5. Survival, treatment patterns, and costs of HER2+ metastatic breast cancer patients in Ontario between 2005 to 2020. Seung SJ; Saherawala H; Moldaver D; Shokar S; Ammendolea C; Brezden-Masley C Breast Cancer Res Treat; 2024 Apr; 204(2):341-357. PubMed ID: 38127177 [TBL] [Abstract][Full Text] [Related]
6. Trastuzumab emtansine for HER2-positive metastatic breast cancer: Outcomes from a whole-of-population Australian cohort. Daniels B; Kiely BE; Tang M; Houssami N; Lord SJ; Pearson SA Breast; 2021 Aug; 58():106-112. PubMed ID: 33992964 [TBL] [Abstract][Full Text] [Related]
7. Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States. Denduluri N; Espirito JL; Hackshaw MD; Wentworth C; Recchia T; Kwong WJ Drugs Real World Outcomes; 2023 Jun; 10(2):177-186. PubMed ID: 36539672 [TBL] [Abstract][Full Text] [Related]
8. Ado-trastuzumab for the treatment of metastatic HER2-positive breast cancer in patients previously treated with Pertuzumab. Al Rabadi LS; Cook MM; Kaempf AJ; Saraceni MM; Savin MA; Mitri ZI BMC Cancer; 2021 Oct; 21(1):1150. PubMed ID: 34706686 [TBL] [Abstract][Full Text] [Related]
9. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Baez-Vallecillo L; Raghavendra AS; Hess KR; Barcenas CH; Moulder SL; Tripathy D; Valero V; Murthy RK Breast Cancer Res Treat; 2019 Jul; 176(1):227-234. PubMed ID: 30977027 [TBL] [Abstract][Full Text] [Related]
10. T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study. Conte B; Fabi A; Poggio F; Blondeaux E; Dellepiane C; D'Alonzo A; Buono G; Arpino G; Magri V; Naso G; Presti D; Mura S; Fontana A; Cognetti F; Molinelli C; Pastorino S; Bighin C; Miglietta L; Boccardo F; Lambertini M; Del Mastro L; Clin Breast Cancer; 2020 Apr; 20(2):e181-e187. PubMed ID: 31735691 [TBL] [Abstract][Full Text] [Related]
11. Impact of Pertuzumab and Ado-Trastuzumab Emtansine on Cumulative Avoidance of Recurrence Among Women Treated for Locally Advanced, Inflammatory, or Early-Stage Nonmetastatic HER2-Positive Breast Cancer in the United States. Sussell JA; Press DJ; Hansen SA; Kim E; Du Toit Y; Fung A Adv Ther; 2023 Sep; 40(9):3857-3874. PubMed ID: 37358705 [TBL] [Abstract][Full Text] [Related]
12. T-DM1 Activity in Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancers That Received Prior Therapy With Trastuzumab and Pertuzumab. Dzimitrowicz H; Berger M; Vargo C; Hood A; Abdelghany O; Raghavendra AS; Tripathy D; Valero V; Hatzis C; Pusztai L; Murthy R J Clin Oncol; 2016 Oct; 34(29):3511-3517. PubMed ID: 27298406 [TBL] [Abstract][Full Text] [Related]
13. Comparison of the efficacy of trastuzumab emtansine between patients with metastatic human epidermal growth factor receptor 2-positive breast cancers previously treated with combination trastuzumab and pertuzumab and with trastuzumab only in Japanese population. Noda-Narita S; Shimomura A; Kawachi A; Sumiyoshi-Okuma H; Sudo K; Shimoi T; Noguchi E; Yonemori K; Shimizu C; Fujiwara Y; Tamura K Breast Cancer; 2019 Jul; 26(4):492-498. PubMed ID: 30737616 [TBL] [Abstract][Full Text] [Related]
14. Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study. Bon G; Pizzuti L; Laquintana V; Loria R; Porru M; Marchiò C; Krasniqi E; Barba M; Maugeri-Saccà M; Gamucci T; Berardi R; Livi L; Ficorella C; Natoli C; Cortesi E; Generali D; La Verde N; Cassano A; Bria E; Moscetti L; Michelotti A; Adamo V; Zamagni C; Tonini G; Barchiesi G; Mazzotta M; Marinelli D; Tomao S; Marchetti P; Valerio MR; Mirabelli R; Russo A; Fabbri MA; D'Ostilio N; Veltri E; Corsi D; Garrone O; Paris I; Sarobba G; Giotta F; Garufi C; Cazzaniga M; Del Medico P; Roselli M; Sanguineti G; Sperduti I; Sapino A; De Maria R; Leonetti C; Di Leo A; Ciliberto G; Falcioni R; Vici P J Exp Clin Cancer Res; 2020 Dec; 39(1):279. PubMed ID: 33302999 [TBL] [Abstract][Full Text] [Related]
15. Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study. Martin M; Fumoleau P; Dewar JA; Albanell J; Limentani SA; Campone M; Chang JC; Patre M; Strasak A; de Haas SL; Xu J; Garcia-Saenz JA Ann Oncol; 2016 Jul; 27(7):1249-56. PubMed ID: 27052654 [TBL] [Abstract][Full Text] [Related]
16. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience. Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517 [TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of trastuzumab emtansine versus lapatinib plus chemotherapy for HER2+ metastatic breast cancer. Ramagopalan SV; Pisoni R; Zenin A; Rathore LS; Ray J; Sammon C J Comp Eff Res; 2021 May; 10(7):595-602. PubMed ID: 33095031 [TBL] [Abstract][Full Text] [Related]
18. Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Current Treatment Standards and Future Perspectives. Dormann C Breast Care (Basel); 2020 Dec; 15(6):570-578. PubMed ID: 33447230 [TBL] [Abstract][Full Text] [Related]
19. Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib Study. Hamilton EP; Kaklamani V; Falkson C; Vidal GA; Ward PJ; Patre M; Chui SY; Rotmensch J; Gupta K; Molinero L; Li Y; Emens LA Clin Breast Cancer; 2021 Dec; 21(6):539-551. PubMed ID: 34154926 [TBL] [Abstract][Full Text] [Related]
20. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2-positive advanced breast cancer: Final results from MARIANNE. Perez EA; Barrios C; Eiermann W; Toi M; Im YH; Conte P; Martin M; Pienkowski T; Pivot XB; Burris HA; Petersen JA; De Haas S; Hoersch S; Patre M; Ellis PA Cancer; 2019 Nov; 125(22):3974-3984. PubMed ID: 31318460 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]